Vivo Bio Tech Ltd. Reports March Quarter Losses and Auditor Concerns

Vivo Bio Tech Ltd. reported a net loss of ₹5.44 crore for its standalone operations and ₹5.16 crore consolidated for the quarter ending March 31, 2026.

Reader Takeaway: Net losses continue, while auditor flags significant statutory dues.

What just happened

Vivo Bio Tech Ltd. announced its financial results for the fourth quarter of the fiscal year 2026. The company registered a standalone net loss of ₹5.44 crore, compared to its consolidated net loss of ₹5.16 crore for the same period. Revenue from operations stood at ₹13.77 crore standalone and ₹14.20 crore consolidated.

Why this matters

The recurring net losses highlight ongoing financial challenges. Additionally, the statutory auditor's emphasis of matter regarding the delayed deposit of undisputed statutory dues totaling ₹4.19 crore, including ₹1.51 crore in TDS and ₹1.90 crore in self-assessment tax, raises concerns about liquidity and compliance.

The backstory

This filing comes after a period of financial reporting where the company has faced profitability challenges. The auditor's note indicates a persistent issue with timely payment of statutory obligations, which could attract regulatory scrutiny.

What changes now

Investors will be closely watching the company's ability to address the outstanding statutory dues and improve its financial performance. The board's approval for re-appointing Mr. Kalyan Ram Mangipudi as Whole-time Director and appointing a consultant for a potential scheme of arrangement signals efforts to stabilize and restructure the business.

Risks to watch

The primary risks include the potential for penalties or legal action due to delayed statutory dues, continued operating losses impacting cash flow, and the uncertainty surrounding the proposed amalgamation or restructuring.

Peer comparison

While specific peer financial data is not provided in the filing, companies in the biotechnology sector often face high R&D costs and lengthy product development cycles, leading to periods of losses. However, timely compliance with statutory requirements is crucial across all industries.

Context metrics (time-bound)

• Standalone Revenue from Operations (Q4 FY26): ₹13.77 crore
• Consolidated Net Loss (Q4 FY26): ₹5.16 crore
• Total Undisputed Statutory Dues Outstanding: ₹4.19 crore (as of March 31, 2026)
• Provident Fund Dues: ₹0.61 crore
• TDS Dues: ₹1.51 crore
• Self-Assessment Tax Dues: ₹1.90 crore

What to track next

Investors should monitor future quarterly results for signs of improved revenue and profitability. The company's progress in resolving the statutory dues and the outcome of the proposed corporate restructuring will be key factors to observe.